Skip to main content

Advertisement

Figure 1 | Diabetology & Metabolic Syndrome

Figure 1

From: The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial

Figure 1

Patient disposition short-term period (week 24) and long-term extension (week 76). Rescued patients include all patients who were rescued in short-term period or long-term extension period. Rescued patients may later have discontinued from the study.*One patient did not enter lead-in period but was directly randomized to double-blind treatment. One patient in the saxagliptin 5 mg q.P.M. group and one patient in the placebo group completed week 24, but discontinued treatment (lost to follow-up and poor compliance, respectively).

Back to article page